Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston enrols first patient in UAE (uterine artery embolisation) trial:

This article was originally published in Clinica

Executive Summary

Boston Scientific's Medi-tech division has enrolled the first patient in a US trial of its minimally invasive uterine artery embolisation (UAE) procedure. The multicentre trial will assess the use of the company's FasTracker325 infusion catheter and Contour-PVA embolic particles as a means of blocking blood flow to the vessels feeding the fibroid. Depriving the fibroid of its blood supply could reduce the symptoms associated with uterine fibroids, says Natick, Massachusetts-based Boston Scientific. Standard treatments for the condition include hysterectomy and myomectomy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel